Skip to main content

Table 3 Most common any-grade (≥ 20% of patients) and grade 3/4 (≥ 10% of patients) TEAEs

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Event, n (%)

Daratumumab 16 mg/kg (n = 32)

Any grade

Grade 3/4

Any TEAE

32 (100.0)

19 (59.4)

Pyrexia

21 (65.6)

4 (12.5)

Thrombocytopenia

9 (28.1)

8 (25.0)

Anemia

9 (28.1)

5 (15.6)

Increased alanine aminotransferase

9 (28.1)

1 (3.1)

Neutropenia

8 (25.0)

6 (18.8)

Headache

8 (25.0)

1 (3.1)

Increased aspartate aminotransferase

8 (25.0)

1 (3.1)

Chills

8 (25.0)

0

Leukopenia

7 (21.9)

5 (15.6)

Fatigue

7 (21.9)

1 (3.1)

  1. TEAE, treatment-emergent adverse event